Clinical Significance of Copeptin or Pentraxin 3 in Prognosis of Artery Stenosis Degree in Stable Coronary Artery Disease Patients

Abstract: This paper investigated the clinical significance of copeptin (CPP)， pentraxin 3 (PTX3)， brain natriuretic peptide (BNP) and phosphodiesterase 9A (PDE9A) in prognosis of stable coronary artery disease (CAD) patients’ artery stenosis degree. A total of 58 patients with stable CAD were divided into two groups by their degree of coronary artery stenosis (group I whose coronary stenosis was ≥70%， n=30; group II whose coronary stenosis was <70%， n=28). There was no significant differences between the two groups’ medical history. Plasma CPP， PTX3， BNP and PDE9A were determined by ELISA. Using binary logistic regression to analyze the correlation. The predictive value of CPP， PTX3， BNP and PDE9A was analyzed by receiver operating characteristic (ROC) curve. Plasma levels of CPP or PTX3 in group I were significantly higher than that of group II (P<0.05)， while there were no statistical significance in plasma levels of BNP or PDE9A between group I and group II. ROC curve analysis showed that the sensitivity of CPP (>1.07 ng/mL) predicts the degree of coronary stenosis was 63.3% and its specificity was 64.3%， the sensitivity PTX3 (>20.56 ng/mL) predicts coronary stenosis was 63.3% and its specificity was 67.9%. CPP or PTX3 can be used as a marker for evaluating whether the coronary stenosis was ≥70% in stable CAD patients; While PDE9A or BNP is not qualified for that use in our acknowledgement.

CSTR: 32200.14.cjcb.2018.07.0017